Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDCI-01 versus tadalafil in pulmonary arterial hypertension (PAH)
ChiCTR2500110083Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DDCI-01 in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Hemodynamic parameters. Started Jul 2022; status: completed.
02
Drugs
DDCI-01
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ChiCTR2500110083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110083.